Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine.
Hum Vaccin Immunother
; 19(1): 2165381, 2023 12 31.
Article
in English
| MEDLINE | ID: covidwho-2187763
ABSTRACT
Herein, we report the case of a 22-year-old woman with hereditary spherocytosis (HS) whose condition worsened after administration of the coronavirus disease 2019 (COVID-19), mRNA vaccine 'BNT162b2 Pfizer-BioNTech.' The woman had been diagnosed with HS in 2005, and her condition remained stable until February 2021. In March 2021, she received the first dose of the above vaccine and experienced pain at the injection site. After the second dose in April 2021, she developed fever and general malaise. Investigations revealed progression of hemolysis, which improved after a few days. To the best of our knowledge, this is the first report of progression of hemolysis in a patient with HS after administration of the mRNA vaccine COVID-19, BNT162b2 'Pfizer-BioNTech.'
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Vaccines
/
COVID-19
Type of study:
Case report
/
Observational study
Topics:
Vaccines
Limits:
Adult
/
Female
/
Humans
/
Young adult
Language:
English
Journal:
Hum Vaccin Immunother
Year:
2023
Document Type:
Article
Affiliation country:
21645515.2023.2165381
Similar
MEDLINE
...
LILACS
LIS